Market Place
Sourcing Support
Pfizer targets broad Talzenna label in prostate cancer
11 Oct 2024 //
FIERCE PHARMA
NICE reverses its call on Talzenna after Pfizer discount
19 Jan 2024 //
FIERCE PHARMA
EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer
08 Jan 2024 //
BUSINESSWIRE
Pfizer`s Talzenna wins broader prostate cancer nod than AZ rival
21 Jun 2023 //
FIERCE PHARMA
FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC
20 Jun 2023 //
ONCOLIVE
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
20 Jun 2023 //
BUSINESSWIRE
Pfizer`s Talzenna staves off prostate cancer in showdown with AZ, J&J
17 Feb 2023 //
FIERCE PHARMA
Senhwa Announces First Patient Dosed in PI Study of Pindnarulex with Talazoparib
31 Oct 2022 //
PRNEWSWIRE
Pfizer, Clovis Make Inroads Against Tough to Treat Prostate Cancer
05 Oct 2022 //
BIOSPACE
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
04 Oct 2022 //
BUSINESSWIRE
Artios initiates Phase 2 study of Pol? Inhibitor ART4215
10 Aug 2022 //
GLOBENEWSWIRE
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Senhwa`s Pindnarulex in Combo with Pfizer`s Talazoparib for Prostate Cancer
06 Jun 2022 //
PRNEWSWIRE
Zenith commences Phase IIb breast cancer combination therapy trial
11 May 2022 //
CLINICALTRIALSARENA
Existing drug could offer new hope for people with secondary breast cancer
13 Oct 2021 //
BREASTCANCER
New BRCA-targeting drug could treat advanced prostate cancer
23 Aug 2021 //
PHARMATIMES
Talazoparib in breast cancer: hint of considerable added benefit
01 Sep 2020 //
IQWIG
Talazoparib Improves QOL, But Not OS in Advanced BRCA1/2+ Breast Cancer
27 Apr 2020 //
ONCLIVE
GSK wins speedy FDA Zejula review in ovarian cancer niche
25 Jun 2019 //
FIERCE PHARMA
BioMarin Earns Milestone Payments from Pfizer for TALZENNA®
22 Jun 2019 //
PR NEWSWIRE
Pfizer’ Talzenna leads latest CHMP highlights
29 Apr 2019 //
PHARMA TIMES
Pfizer Gets Positive CHMP Opinion for Talzenna
26 Apr 2019 //
PRESS RELEASE
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
04 Dec 2018 //
XCONOMY
Myriad Announces New Laboratory Agreement with Pfizer®
07 Nov 2018 //
GLOBENEWSWIRE
Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins
17 Oct 2018 //
ENDPTS
Can Pfizer`s Talzenna really make a dent in the PARP field?
17 Oct 2018 //
FIERCE PHARMA
BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib)
16 Oct 2018 //
PR NEWSWIRE
How Sensitive Is Pfizer To R&D Expense Changes?
04 Jul 2018 //
FORBES
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review
18 Jun 2018 //
GLOBENEWSWIRE
Pfizer wins appeal of £84M fine over U.K. epilepsy drug price hike
09 Jun 2018 //
FIERCE PHARMA
Pfizer files PARP inhibitor for breast cancer in US, EU
09 Jun 2018 //
PHARMA TIMES
PARP battle heats up as Pfizer nabs priority review in breast cancer
08 Jun 2018 //
FIERCE PHARMA
Mega-blockbuster? Pfizer lines up for a snap review of its PARP drug talazoparib
08 Jun 2018 //
ENDPTS
BioMarin Receives Milestone Payments from Pfizer for Talazoparib
07 Jun 2018 //
PR NEWSWIRE
Scientists Identify Why Some People May Be Resistant To PARP Inhibitor Drugs
10 May 2018 //
FORBES
Pfizer announces talazoparib significantly extends PFS in phase 3 EMBRACA
11 Dec 2017 //
PHARMABIZ
